TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07734844: A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

Sponsor: Kodiak Sciences Inc · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 910 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07734844 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07734844 Rescue Dossier →